Optibrium Expands US and UK Operations
Dr Scott Lyon, Director of BD, Optibrium
Optibrium, a developer of software for small molecule drug discovery, announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK.
Optibrium’s move to larger premises is driven by the company’s rapid recent growth and will accommodate future expansion plans as it accelerates its R&D pipeline and extends research into new technologies to improve the efficiency and productivity of the drug discovery process. In the last year Optibrium has grown by 60%, expanding its computational chemistry, software development and application science teams.
As part of this growth strategy, Dr. Scott Lyon joins Optibrium on the west coast of North America, where he has responsibility for supporting the company’s existing client base and for developing new business opportunities for StarDrop and the company’s range of products for small molecule design, optimisation and data analysis. Scott brings 20 years of experience in business development and support for scientific software and services, having previously worked at organisations including MDL, CambridgeSoft and Thomson Reuters. He has BSc from Carnegie Mellon University and a PhD in Chemistry from the University of Arizona.
Dr Matthew Segall, Optibrium’s CEO, commented: “As we move to larger, custom-designed offices, it is encouraging to see that our ongoing investment in the best scientists and engineers, who deliver cutting-edge features to our users, has resulted in strong revenue growth and thus sets the foundations for further expansion.
“We are pleased to welcome Scott to the US team and look forward to him developing our west coast community, building on our success by providing local support to our clients and maintaining Optibrium’s reputation for excellence in customer service.”
Dr Scott Lyon added: “Optibrium’s unique drug discovery software and dedication to its clients offers a great opportunity to build for success. I am delighted to join the team and contribute to the company’s further development.”
“Lymphoma Micro-reactor” Targets Chemo-Resistant LymphomaNews
Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.READ MORE
Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat MelanomaNews
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018